Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial
| Condition | Intervention |
|---|---|
|
Coronary Artery Calcification |
Procedure: CT Cardiac |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Association Between NAFLD and Coronary Artery Calcification |
- Total calcium score measurement [ Time Frame: 1 month ] [ Designated as safety issue: No ]total calcium score will be measured
| Estimated Enrollment: | 120 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | March 2012 |
| Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: CT cardiac
the patient will undergo cardiac CT
|
Procedure: CT Cardiac
the patient will undergo cardiac CT
|
Detailed Description:
Coronary artery disease are 8 times more prevalent in patients with NAFLD that the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial. AIM: the aim is to evaluate the association between CAC score ( CT) and NAFLD (CT). the working hypothesis is that Beside the traditional risk factors including age, diabetes, NAFLD is also associated with moderate to high risk of CAD.
Eligibility| Ages Eligible for Study: | 45 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who will undergo cardiac CT for patients with low to intermediate risk for CAD
Exclusion Criteria:
- Patients with PCI or CABG will be excluded
Contacts and Locations| Contact: Assy Nimer, MD | +97246828445 | assy.n@ziv.health.gov.il |
| Israel | |
| Ziv medical center liver unit | Not yet recruiting |
| Safed, Israel, Israel, 13100 | |
| Contact: Nimer Assy, MD +972-46828445 assy.n@ziv.health.gov.il | |
More Information
No publications provided
| Responsible Party: | Liver Clinic, Ziv medical center |
| ClinicalTrials.gov Identifier: | NCT01158066 History of Changes |
| Other Study ID Numbers: | NAFLD and CAC |
| Study First Received: | July 4, 2010 |
| Last Updated: | April 5, 2011 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Ziv Hospital:
|
NAFLD Calcium score Liver Fat Visceral fat |
excessive visceral fat excessive liver fat accumulation Biomarkers of insulin resistance (HOMA), inflammation (CRP) and (MDA-Paraoxonase) |
Additional relevant MeSH terms:
|
Calcinosis Fatty Liver Coronary Artery Disease Arteriosclerosis Calcium Metabolism Disorders Metabolic Diseases Liver Diseases |
Digestive System Diseases Coronary Disease Myocardial Ischemia Heart Diseases Cardiovascular Diseases Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on June 18, 2013